How much cash does Maze Therapeutics, Inc. Common Stock generate?

Maze Therapeutics, Inc. Common Stock (MAZE) generated -$121.5M in operating cash flow over the trailing twelve months.

What is Maze Therapeutics, Inc. Common Stock's free cash flow?

After $588.0K of capital expenditures, Maze Therapeutics, Inc. Common Stock's free cash flow was -$122.1M over the trailing twelve months.

Where does Maze Therapeutics, Inc. Common Stock's cash flow data come from?

Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Maze Therapeutics, Inc. Common Stock MAZE Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25
Net income	-$131.12M—
Depreciation and amortization	$2.4M-27.1%
Stock-based compensation	$16.4M+70.0%
Amortization of debt issuance costs	——
Change in accounts payable	-$27K—
Change in accrued liabilities	——
Change in other assets	$2.94M—
Change in other liabilities	$3.48M—
Other working capital changes	——
Change in operating lease liabilities	-$3.32M-14.0%
Change in receivables	——
Net cash from operating activities	-$111.94M—
Capital expenditures	$794K-30.8%
Net cash from investing activities	-$170.96M-14,805%
Proceeds from issuance of debt	——
Proceeds from issuance of common stock	$5.56M+659%
Payment of debt issuance costs	——
Proceeds from issuance of preferred stock	——
Net cash from financing activities	$275.34M+190%
Net increase (decrease) in cash	-$7.57M—
Income taxes paid	——
Accretion (Amortization) of Discounts and Premiums, Investments	——
Non-cash interest expense	——
Depreciation	$2.4M-27.1%
Accrued expenses and other liabilities	——
Operating lease liabilities	-$3.32M-14.0%
Other long-term liabilities	——
Increase (Decrease) in Other Operating Assets	——
Increase (Decrease) in Prepaid Expense and Other Assets	$2.94M—
Payment Of Success Fee Derivative	——
Payments Of Debt Issuance Costs	——
Payments Of Stock Issuance Costs	——
Net proceeds from sales of subsidiary shares	——
Proceeds from issuances of debt	——
Proceeds From Warrant Exercises	$1K—
Accrued payables for capital expenditures	——
Debt Issuance Costs Recorded In Accounts Payable And Accrued Expenses	——
Deemed Dividend For Antidilution Adjustments To Series B And C Redeemable Convertible Preferred Stock Upon Issuance Of Series D Redeemable Convertible Preferred Stock	——
Deferred Offering Costs Recorded In Accrued Expenses	——
Increase Decrease In Operating Lease Liability	-$3.32M-14.0%
Operating Lease Expense	$3.13M+8.5%
Settlement Of Convertible Promissory Notes By Conversion To Series D1Redeemable Convertible Preferred Stock	——
Free cash flow	-$112.73M—
Free cash flow	-$112.73M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Maze Therapeutics, Inc. Common Stock.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Maze Therapeutics, Inc. Common Stock generate?: Maze Therapeutics, Inc. Common Stock (MAZE) generated -$121.5M in operating cash flow over the trailing twelve months.
What is Maze Therapeutics, Inc. Common Stock's free cash flow?: After $588.0K of capital expenditures, Maze Therapeutics, Inc. Common Stock's free cash flow was -$122.1M over the trailing twelve months.
Where does Maze Therapeutics, Inc. Common Stock's cash flow data come from?: Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.